| AASLD

Home

HIGH DOSES OF ALBUMIN INCREASES MORTALITY AND COMPLICATIONS IN TERLIPRESSIN TREATED PATIENTS WITH CIRRHOSIS: INSIGHTS FROM THE ATTIRE TRIAL

Read more about HIGH DOSES OF ALBUMIN INCREASES MORTALITY AND COMPLICATIONS IN TERLIPRESSIN TREATED PATIENTS WITH CIRRHOSIS: INSIGHTS FROM THE ATTIRE TRIAL

<div>Background: The CONFIRM trial revealed potential harm with terlipressin in a subset of patients, who developed respiratory failure. It remains unclear to what degree concomitant albumin contributes to the undesirable outcomes of terlipressin treatment. Using ATTIRE trial data, we compared safety of serum targeted albumin infusions to standard-of-care in patients with cirrhosis receiving terlipressin.

NEGATIVE IMPACT OF PNPLA3 rs738409 C>G IS SIGNIFICANTLY MODIFIED BY DIETARY FACTORS, CAFFEINE AND NON-HEAVY ALCOHOL CONSUMPTION IN THE US POPULATION

Read more about NEGATIVE IMPACT OF PNPLA3 rs738409 C>G IS SIGNIFICANTLY MODIFIED BY DIETARY FACTORS, CAFFEINE AND NON-HEAVY ALCOHOL CONSUMPTION IN THE US POPULATION

<div>Background: PNPLA3 rs738409 C>G is strongly associated with NAFLD and its severity. PNPLA3 expression is highly regulated by changes in energy balance; however, little is known about the interplay between PNPLA3, dietary factors, alcohol intake, and risk of liver-related death (LRD).

LOW ANTIVIRAL TREATMENT RATE FOR PATIENTS WITH HEPATITIS C (HCV)-RELATED HEPATOCELLULAR CARCINOMA (HCC)– A REAL-WORLD NATIONWIDE U.S. STUDY

Read more about LOW ANTIVIRAL TREATMENT RATE FOR PATIENTS WITH HEPATITIS C (HCV)-RELATED HEPATOCELLULAR CARCINOMA (HCC)– A REAL-WORLD NATIONWIDE U.S. STUDY

<div>Background: All-oral interferon-free direct-acting antiviral agents (DAAs) for treatment and cure of hepatitis C virus (HCV) became available in 2013-2014. Our primary objective is to determine the proportion of patients with HCV-related HCC who received DAA after 2014 and factors associated with treatment receipt. We also evaluated DAA treatment impact on the overall survival in this population as a secondary outcome.

SIMULTANEOUS LIVER TRANSPLANT AND SLEEVE GASTRECTOMY IS A SAFE SURGICAL OPTION THAT IMPROVES METABOLIC SYNDROME AND REDUCES ALLOGRAFT STEATOSIS

Read more about SIMULTANEOUS LIVER TRANSPLANT AND SLEEVE GASTRECTOMY IS A SAFE SURGICAL OPTION THAT IMPROVES METABOLIC SYNDROME AND REDUCES ALLOGRAFT STEATOSIS

<div>Background: The prevalence of obesity and metabolic syndrome (MS) is rising dramatically among liver transplant (LT) candidates, many of whom have NASH. Following LT, untreated MS often causes recurrent NAFLD and NASH. Several small case series describe bariatric surgery pre-, post-, or concurrently with LT as a treatment for MS. We reviewed our experience with LT and concurrent sleeve gastrectomy (LTSG) with aims to determine long-term safety, efficacy, and impact on progression of MS and liver disease after transplantation.

SINGLE-CELL ANALYSIS OF LIVER FINE NEEDLE ASPIRATES REVEALS DIFFERENCES IN GENE EXPRESSION BETWEEN CHRONIC HBV-MONOINFECTED VERSUS HBV/HIV-COINFECTED ADULTS

Read more about SINGLE-CELL ANALYSIS OF LIVER FINE NEEDLE ASPIRATES REVEALS DIFFERENCES IN GENE EXPRESSION BETWEEN CHRONIC HBV-MONOINFECTED VERSUS HBV/HIV-COINFECTED ADULTS

<div>Background: HIV infection accelerates the natural history of HBV-related liver disease. The mechanisms by which this occurs are incompletely understood due to limited access to comparable groups of people living with HBV with/without HIV and lack of access to the liver compartment.

GENETIC ABLATION OF CD4 T CELLS IN MICE ATTENUATES LIVER INJURY, INFLAMMATION, AND FIBROSIS IN NONALCOHOLIC STEATOHEPATITIS

Read more about GENETIC ABLATION OF CD4 T CELLS IN MICE ATTENUATES LIVER INJURY, INFLAMMATION, AND FIBROSIS IN NONALCOHOLIC STEATOHEPATITIS

<div>Background: Nonalcoholic steatohepatitis (NASH) is a progressive condition characterized by excessive inflammation, which may lead to fibrosis. To date, the contribution of T cells to NASH remains largely unexplored. Our unpublished data suggest that CD4 T cells with pathogenic Th1 phenotype accumulate in murine NASH livers. Therefore, we investigated the role of CD4 T lymphocytes in NASH development.

POSITIVE RESULTS FROM THE ALPINE 4 STUDY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 2b TRIAL EVALUATING MULTIPLE DOSES OF THE FGF19 ANALOGUE ALDAFERMIN IN PATIENTS WITH COMPENSATED CIRRHOSIS DUE TO NONALCOHOLIC STEATOHEPATITIS

Read more about POSITIVE RESULTS FROM THE ALPINE 4 STUDY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 2b TRIAL EVALUATING MULTIPLE DOSES OF THE FGF19 ANALOGUE ALDAFERMIN IN PATIENTS WITH COMPENSATED CIRRHOSIS DUE TO NONALCOHOLIC STEATOHEPATITIS

<div>Background: Patients with cirrhosis are at increased risk of liver decompensation and HCC which can result in liver transplant or death. There is no available therapy and previous clinical trials have failed to show a benefit in patients with NASH and cirrhosis. Aldafermin, an engineered analog of the human hormone FGF19, improved liver histology in previous non-cirrhotic, phase 2 trials.

ER-ASSOCIATED PROTEIN DEGRADATION AS A POTENTIAL ANTI-FIBROTIC TARGET IN HEPATIC STELLATE CELLS

Read more about ER-ASSOCIATED PROTEIN DEGRADATION AS A POTENTIAL ANTI-FIBROTIC TARGET IN HEPATIC STELLATE CELLS

<div>Background: Liver injury activates hepatic stellate cells (HSCs) which drive fibrosis through secreting extracellular matrix proteins. Proteins destined for secretion are cotranslationally translocated into the endoplasmic reticulum (ER), folded, and exported for secretion. Activated HSCs exhibit increased protein translation leading to ER stress, which is sensed by ER membrane proteins Activating transcription factor 6 (ATF6α), Inositol-requiring enzyme 1 (IRE1α), and Protein kinase R-like ER kinase (PERK).

Addition of rifaximin to broad-spectrum antibiotics has no beneficial role in critically ill cirrhosis patients with acute overt hepatic encephalopathy- A double-blind, randomized controlled trial

Read more about Addition of rifaximin to broad-spectrum antibiotics has no beneficial role in critically ill cirrhosis patients with acute overt hepatic encephalopathy- A double-blind, randomized controlled trial

<div>Background: Critically ill cirrhosis (CIC) patients admitted to the intensive care unit (ICU) are usually on broad-spectrum intravenous antibiotics due to suspected infection or as a protocol. Few reports have suggested rifaximin to be beneficial in acute overt hepatic encephalopathy (OHE). However, the role of rifaximin in patients on broad-spectrum antibiotics admitted to ICU is still unclear. Therefore, we aimed to assess the efficacy of addition of rifaximin to broad-spectrum antibiotics for CIC patients admitted to ICU for OHE.

SERUM PROTEOMICS REVEALS UNIQUE ASSOCIATION OF CCL24 WITH DISEASE-RELATED PATHWAYS AND SIGNATURES IN PRIMARY SCLEROSING CHOLANGITIS

Read more about SERUM PROTEOMICS REVEALS UNIQUE ASSOCIATION OF CCL24 WITH DISEASE-RELATED PATHWAYS AND SIGNATURES IN PRIMARY SCLEROSING CHOLANGITIS

<div>Background: Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by inflammation and fibrosis of the bile ducts. CCL24 (Eotaxin-2) is a chemokine that promotes inflammation and fibrosis and is overexpressed in the liver of patients with PSC, particularly in areas with biliary injury. Previous studies showed that blocking CCL24 interferes with core pathways that contribute to PSC pathophysiology in preclinical models.

Subscribe to